HTA - - Health Technology Assessment Report

Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis (Structured abstract)

Code: HTA-32016000894 **Year:** 2015 **Date:** 2015

Author: Hernández-Vásquez A

Interventions

Tobramycin inhalation powder versus Tobramycin inhalation solution

Main results

There is moderate quality evidence, including a single study comparing both inhalation modes. No significant differences were found in clinically significant results between tobramycin inhalation solution and tobramycin inhalation powder.

Authors' conclusions

The clinical practice guidelines and coverage policies found do not consider tobramycin inhalation powder as a first line treatment and in some cases, they mention it as a treatment alternative only under certain conditions such as intolerance or no response to colistin solution, colistin powder or tobramycin inhalation solution; and with price reduction agreements that make tobramycin inhalation power more affordable.

http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32016000894/frame.html

See also

Health Technology Assessment Database- Institute for Clinical Effectiveness and Health Policy (IECS)

Keywords

Anti-Bacterial Agents; Bacterial Infections; Infection; Inhalation OR nebulised; pharmacological_intervention; Powders; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections; Tobramycin; Aminoglycosides;